Solvent used in nail polish may increase risk of breast and ovarian cancer

NewsGuard 100/100 Score

Ethylene glycol methyl ether a solvent for nitrocellulose, oils and resins, adhesives and for many different purposes may raise the risk of breast or ovarian cancer among women taking hormone treatments, say researchers at Duke University. Ethylene glycol methyl ether is used in formulating cleaners, printing inks, photographic film, lacquers, and nail polish.

Ethylene glycol methyl ether (EGME) was found to boost the activity of hormones used in HRT and the contraceptive pill which in turn may increase the risk of breast or ovarian cancer for some women

The researchers also found the same effect was triggered by a drug used to treat epilepsy, Vaproic acid, which has a similar chemical structure.

Ethylene glycol methyl ether was found to boost hormone activity by up to 10 times. Researchers suggested that this could be particularly significant for women vulnerable to developing forms of cancer which are triggered by hormones. The research also hinted at a possible link between Ethylene glycol methyl ether exposure and miscarriage.

Dr Donald McDonnell, lead researcher said: "Our study demonstrates that these chemicals boost the activity of estrogens and progestins inside cells by up to eight to 10 fold."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy